BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially 2018 Revenue Guidance Revised Upward

T-cell graphic

On April 2, 2018, BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary revenue for the three months ended March 31, 2018. First quarter 2018 preliminary revenue from sales of BioLife’s proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million, […]

This website uses cookies to ensure you get the best experience on our website.